Organ-sparing vs. surgery for special GI cancers after immunotherapy
Part of Cancer, Digestive system clinical trials.
This trial compares two approaches for patients with certain types of stomach or colon cancer that have specific genetic features (dMMR, MSI-H, or POLE mutations) and have responded well to immunotherapy: either closely monitoring without surgery, or proceeding with surgery. The goal is to see if some patients can safely avoid surgery while maintaining good outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with cancer of the stomach, colon, or junction between esophagus and stomach (confirmed by biopsy)
- Your cancer has one of three specific genetic features: dMMR, MSI-H, or POLE mutations (confirmed by lab testing)
- You received immunotherapy (checkpoint inhibitor drugs) before being evaluated for this trial
- Age 18 or older when first diagnosed with cancer
- Good overall health status, able to tolerate treatment and follow-up care
- Able to attend regular imaging, endoscopy (camera exams), and clinical visits for monitoring
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with certain types of gastrointestinal cancers that have a genetic feature called MSI-H/dMMR or POLE mutation. It looks at whether, after immunotherapy, you can avoid surgery or have a less invasive procedure instead, such as watching and waiting, endoscopic removal, or limited surgery.
This study is looking at whether people with certain gastrointestinal cancers who have had a very good response to targeted therapy or immunotherapy might be able to avoid surgery for now and instead be closely monitored. The goal is to see if this non-surgical approach is safe and effective.
This trial tests a less invasive surgery approach for early-stage colon cancer. It uses a special dye to find and remove only the first lymph node (sentinel node) while removing just the part of the colon with the tumor, possibly avoiding a bigger surgery.
This study tests whether giving personalized follow-up treatment after stomach cancer surgery and chemotherapy can help prevent the cancer from coming back. The treatment plan is tailored based on how well the tumor responded to initial chemotherapy.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests different adjuvant treatments for patients who had stomach or gastroesophageal junction cancer, received chemotherapy with immunotherapy before surgery, and had a complete response (no cancer left) in the surgical sample. It aims to find which treatment works best to prevent the cancer from coming back.
Hear when a new Gastrointestinal Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.